The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN682218     1-(2-hydroxyethyl)-2- (hydroxymethyl)piperi...

Synonyms: AG-L-66180, BAY-m 1099, AC-1288, AC1L1BDA, Bay 1099, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MIGLITOL


High impact information on MIGLITOL

  • OBJECTIVE: To assess the long-term safety and effectiveness of a titrated dose of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in Hispanic NIDDM patients [4].
  • This resulted in the AUC for plasma insulin to be significantly less with Bay-m-1099 (AUC, 8.2 +/- 1.3 vs. 12.8 +/- 1.6 microU/ml/min with placebo; P less than 0.01) [1].
  • The major part of alpha 1-antitrypsin secreted by Bay m 1099 treated cells still carried two complex type oligosaccharide chains, the majority of alpha 1-acid glycoprotein carried three to five [5].
  • After removal of Bay m 1099 from hepatocytes its inhibitory effect on protein glycosylation was immediately reversible [5].
  • The effect of the glucose analogue N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of alpha-glucosidases was studied in human fibroblasts and HepG2 cells [6].

Chemical compound and disease context of MIGLITOL


Biological context of MIGLITOL

  • As miglitol (BAY m-1099), an absorbable alpha-glucosidase inhibitor, can inhibit glycogenolysis, we investigated whether 200 mg miglitol ingested at bedtime could decrease fasting blood glucose values [7].
  • The present study aimed at investigating the metabolic effects and tolerance of two desoxynojirimycin derivatives with alpha-glucosidase inhibitory properties (BAY m 1099 and BAY o 1248) [8].

Anatomical context of MIGLITOL

  • Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells [6].

Associations of MIGLITOL with other chemical compounds

  • The inhibition of lactase activity was stronger by Bay-m-1099 (Ki = 4.9 X 10(-6) M) than by Bay-o-1248 (Ki = 6.7 X 10(-5) M) [9].
  • A rapid, sensitive and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of miglitol (CAS 72432-03-2), an alpha-glucosidase inhibitor, in human plasma using gabapentin (CAS 60142-96-3) as internal standard (IS) [10].

Gene context of MIGLITOL


Analytical, diagnostic and therapeutic context of MIGLITOL

  • Fifteen obese Type II diabetic patients with inadequate metabolic control during sulphonylurea treatment received a standardized diet and were treated either with Bay m 1099, b.d. (100 mg before breakfast and dinner) or placebo for 3 days, according to a double-blind cross-over design [13].
  • 1. The effect of the acute or chronic oral administration of miglitol (Bay M 1099 alpha-glucosidase inhibitor) to non-insulin-dependent diabetic rats was studied [14].


  1. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus. Kennedy, F.P., Gerich, J.E. Clin. Pharmacol. Ther. (1987) [Pubmed]
  2. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Mitrakou, A., Tountas, N., Raptis, A.E., Bauer, R.J., Schulz, H., Raptis, S.A. Diabet. Med. (1998) [Pubmed]
  3. Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM). Kennedy, F.P., Gerich, J.E. Diabetes Res. Clin. Pract. (1988) [Pubmed]
  4. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Johnston, P.S., Feig, P.U., Coniff, R.F., Krol, A., Davidson, J.A., Haffner, S.M. Diabetes Care (1998) [Pubmed]
  5. Effect of the alpha-glucosidase inhibitor N-hydroxyethyl-1-deoxynojirimycin (Bay m 1099) on the biosynthesis of liver secretory glycoproteins. Ludolph, D., Gross, V., Katz, N.R., Giffhorn-Katz, S., Kreisel, W., Heinrich, P.C., Gerok, W. Biochem. Pharmacol. (1989) [Pubmed]
  6. Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells. Wisselaar, H.A., van Dongen, J.M., Reuser, A.J. Clin. Chim. Acta (1989) [Pubmed]
  7. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus. Sels, J.P., Kingma, P.J., Wolffenbuttel, B.H., Menheere, P.P., Branolte, J.H., Nieuwenhuijzen Kruseman, A.C. The Netherlands journal of medicine. (1994) [Pubmed]
  8. Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics. Gerard, J., Hillebrand, I., Lefèbvre, P.J. International journal of clinical pharmacology, therapy, and toxicology. (1987) [Pubmed]
  9. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Samulitis, B.K., Goda, T., Lee, S.M., Koldovský, O. Drugs under experimental and clinical research. (1987) [Pubmed]
  10. Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. Nirogi, R.V., Kandikere, V.N., Shukla, M., Mudigonda, K., Maurya, S., Boosi, R., Yerramilli, A. Arzneimittel-Forschung. (2006) [Pubmed]
  11. Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Lembcke, B., Fölsch, U.R., Creutzfeldt, W. Digestion (1985) [Pubmed]
  12. The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats. DeBouno, J.F., Michaelis, O.E., Tulp, O.L. Gen. Pharmacol. (1993) [Pubmed]
  13. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients. Schnack, C., Röggla, G., Luger, A., Schernthaner, G. Eur. J. Clin. Pharmacol. (1986) [Pubmed]
  14. Effect of miglitol administration to non-insulin-dependent diabetic rats. Tormo, M.A., Ropero, M.F., Nieto, M., Martinez, I.M., Campillo, J.E. Gen. Pharmacol. (1998) [Pubmed]
WikiGenes - Universities